Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin
- PMID: 1698787
Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin
Abstract
The interaction of plasminogen activator inhibitor-1 (PAI-1) with its binding protein vitronectin (VN) (Declerck, P. J., De Mol, M., Alessi, M.-C., Baudner, S., Paques, E.-P., Preissner, K. T., Müller-Berghaus, G., and Collen, D. (1988) J. Biol. Chem. 263, 15454-15461) in the extracellular matrix (ECM) of cultured human endothelial cells (HUVEC) was studied. Like PAI-1, VN was found associated with the ECM as evidenced by direct antibody binding, by Western blot analysis as well as by diffuse immunofluorescence staining in permeabilized HUVEC. The specific interaction of VN with confluent monolayers of HUVEC was found to be saturable within 2-4 h at 37 degrees C only with respect to binding to the cells, while no saturable binding to the underlying ECM was observed, indicating that the majority if not all ECM-associated VN was derived from the culture medium. In contrast to PAI-1, ECM-associated VN was resistant toward glycine (pH 2.3), guanidine or urokinase treatment, suggesting that VN was tightly associated with the ECM network. Binding of recombinant PAI-1 (rPAI-1) was largely blocked by anti-VN IgG and only partly by anti-collagen IgG but not by antibodies against other ECM components, indicating that VN constitutes the primary binding protein for ECM-associated PAI-1. This contention was supported by ligand blotting experiments in which rPAI-1 was reacted with nitrocellulose replicas of electrophoretically separated ECM components. Protein band(s) (Mr = 63,000-67,000), comigrating with bovine VN (i.e. medium-derived VN) rather than with human VN were identified as major binding component(s). Moreover, binding studies with purified components revealed that PAI-1 did not show any affinity for collagen (type I/III) alone, whereas VN collagen coating was a much better template for PAI-1 binding than VN alone and that conformationally extended VN provides maximal PAI-1 binding capacity. Binding of rPAI-1 to surface-coated VN was saturable and revealed that (unlike urokinase) heparin or the synthetic peptide Gly-Arg-Gly-Asp-Ser did not inhibit PAI-1 binding. Ligand binding of rPAI-1 to nitrocellulose replicas from sodium dodecyl sulfate-polyacrylamide gels containing electrophoretically separated peptides from VN digests documented the association of PAI-1 with Mr = 10,000-20,000 fragments originating from the heparin-binding domain of VN. These results indicate that the exposure of the glycosaminoglycan-binding domain in VN may allow the concomitant binding of PAI-1 and heparin-like molecules to this region of the VN molecule.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.J Biol Chem. 1992 Jun 15;267(17):12098-105. J Biol Chem. 1992. PMID: 1376317
-
Binding of plasminogen activator inhibitor type-1 to extracellular matrix of Hep G2 cells. Evidence that the binding protein is vitronectin.J Biol Chem. 1991 Mar 5;266(7):4334-40. J Biol Chem. 1991. PMID: 1705551
-
Serum-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor.J Cell Biol. 1990 Sep;111(3):1283-91. doi: 10.1083/jcb.111.3.1283. J Cell Biol. 1990. PMID: 1697297 Free PMC article.
-
Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin.Cell Differ Dev. 1990 Dec 2;32(3):287-92. doi: 10.1016/0922-3371(90)90041-t. Cell Differ Dev. 1990. PMID: 1711915 Review.
-
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.Biol Chem. 2002 Jul-Aug;383(7-8):1143-9. doi: 10.1515/BC.2002.125. Biol Chem. 2002. PMID: 12437099 Review.
Cited by
-
Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.J Cell Biol. 1991 Dec;115(6):1773-81. doi: 10.1083/jcb.115.6.1773. J Cell Biol. 1991. PMID: 1721912 Free PMC article.
-
Functional stability of plasminogen activator inhibitor-1.ScientificWorldJournal. 2014;2014:858293. doi: 10.1155/2014/858293. Epub 2014 Oct 15. ScientificWorldJournal. 2014. PMID: 25386620 Free PMC article. Review.
-
Identification of a PAI-1-binding site within an intrinsically disordered region of vitronectin.Protein Sci. 2020 Feb;29(2):494-508. doi: 10.1002/pro.3770. Epub 2019 Nov 20. Protein Sci. 2020. PMID: 31682300 Free PMC article.
-
Characterization of an Extensive Interface on Vitronectin for Binding to Plasminogen Activator Inhibitor-1: Adoption of Structure in an Intrinsically Disordered Region.Biochemistry. 2019 Dec 24;58(51):5117-5134. doi: 10.1021/acs.biochem.9b00605. Epub 2019 Dec 16. Biochemistry. 2019. PMID: 31793295 Free PMC article.
-
Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I.J Cell Biol. 1993 May;121(3):679-87. doi: 10.1083/jcb.121.3.679. J Cell Biol. 1993. PMID: 7683690 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous